What are the indications, dosing regimen, administration method, contraindications, common adverse effects, and monitoring recommendations for talimogene laherparepvec (T‑VEC) in patients with unresectable melanoma?

Talimogene Laherparepvec (T-VEC) for Unresectable Melanoma

T-VEC is FDA-approved for intralesional treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions recurrent after initial surgery, but it has NOT been shown to improve overall survival or affect visceral metastases. 1

Indications

T-VEC is indicated for:

• Local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma recurrent after initial surgery 1
• Patients with injectable (cutaneous, subcutaneous, or nodal) unresectable lesions who are not eligible for or refuse recommended systemic therapies (anti-PD-1 or combination therapies) 2

Critical limitation: T-VEC has no demonstrated benefit for visceral metastases and does not improve overall survival 1. The ASCO guideline rates this as weak recommendation with low evidence quality 2.

Neoadjuvant Setting

The NCCN 2024 guidelines recommend T-VEC as Category 2A for:

• Resectable stage III (clinical satellite/in-transit disease)
• Local satellite/in-transit recurrence
• Followed by surgery 3

This is based on a phase II trial showing improved 2-year RFS (29.5% vs 16.5%) and OS (88.9% vs 77.4%) when T-VEC preceded surgery, though efficacy is modest for lymph node disease 3.

Dosing Regimen

Initial Dose

• Up to 4 mL total of 10^6 PFU/mL concentration (light green cap vial)
• Inject largest lesions first, then prioritize by size until maximum volume reached 1

Second Dose (3 weeks after initial)

• Up to 4 mL total of 10^8 PFU/mL concentration (royal blue cap vial)
• Inject any NEW lesions first, then prioritize remaining lesions by size 1

All Subsequent Doses (every 2 weeks)

• Up to 4 mL total of 10^8 PFU/mL concentration
• Continue injecting new lesions first, then by size priority 1

Volume Per Individual Lesion

• >5 cm: up to 4 mL
• >2.5 to 5 cm: up to 2 mL
• >1.5 to 2.5 cm: up to 1 mL
• >0.5 to 1.5 cm: up to 0.5 mL
• ≤0.5 cm: up to 0.1 mL 1

Treatment duration: Continue for at least 6 months unless other treatment is required or no injectable lesions remain. Reinitiate if new lesions appear after complete response 1.

Administration Method

• Intralesional injection only - never administer intravenously 1
• Inject into visible, palpable, or ultrasound-detectable lesions 1
• When lesions are clustered, inject as a single lesion 1
• Not all lesions need to be injected at each visit; previously injected or uninjected lesions can be treated at subsequent visits 1

Storage and Handling

• Store at -90°C to -70°C (-130°F to -94°F) 1
• Protect from light 1
• Single-use vials only 1

Contraindications and Precautions

Absolute Contraindications

• Immunosuppressed patients (though one case report showed response with physiologic corticosteroid replacement for adrenal insufficiency) 4
• Pregnancy (theoretical risk given viral nature)

Major Warnings

• Herpetic infection risk: Can cause life-threatening disseminated herpes infection 1
• Avoid in patients with active herpetic infections
• Use extreme caution in immunocompromised states 1

Infection Control Measures

Patients must:

• Cover treatment sites with airtight and watertight dressings for at least 1 week after each treatment (longer if weeping/oozing) 1
• Avoid direct contact between treatment sites/dressings/body fluids and close contacts 1
• Use condoms during sexual activity 1
• Avoid kissing if either party has open mouth sores 1
• Wear gloves when changing dressings 1
• Place used dressings in sealed plastic bags and dispose in garbage 1

Common Adverse Effects

The adverse effect profile is distinct from systemic immunotherapies - predominantly mild to moderate and rarely leading to discontinuation 5:

Most Common (from clinical trials)

• Chills: 92% (mostly grade 1-2) 3, 21.69% in systematic review 6
• Headache: 92% 3
• Pyrexia/Fever: 77% 3, 20.41% 6
• Flu-like symptoms: 14.89% 6
• Fatigue/Tiredness 1
• Nausea 1
• Pain at injection site 1

Serious Adverse Effects (Rare)

• Grade 3 diarrhea: 15% in one neoadjuvant study 3
• No grade 4 events or treatment-related deaths in major trials 3
• Herpetic infection (local or disseminated) 1

Critical warning signs requiring immediate medical attention:

• Pain, burning, tingling, or blisters around mouth, genitals, or any body part
• Eye pain, light sensitivity, discharge, or blurry vision
• Weakness in arms or legs
• Extreme drowsiness
• Mental confusion 1

Monitoring Recommendations

During Treatment

• Monitor for signs of herpetic infection at each visit 1
• Assess injection sites for proper healing
• Clinical assessment with or without imaging to determine treatment response or progression 3
• Report adverse events to Amgen at 1-855-IMLYGIC (1-855-465-9442) for follow-up testing if needed 1

Response Assessment

• Responses may be delayed or occur after pseudoprogression (similar to other immunotherapies) 5
• In stage IIIB-IVM1c patients: 64% of injected lesions and 34% of uninjected non-visceral lesions decreased by ≥50% 5
• Durable responses (≥6 months) occur in >50% of responders 5
• Overall response rate: 62-67% in real-world data 6, 7
• Complete response rate: 35% 7

Long-term Follow-up

• Median PFS: 12.2 months (real-world data) 7
• Median OS: 35.5 months (real-world data) 7
• 95% of patients achieving complete response remained alive and progression-free at median 19.1 months follow-up 7

Clinical Context and Positioning

T-VEC is NOT equivalent to first-line systemic therapies (anti-PD-1 monotherapy, nivolumab/ipilimumab, or BRAF/MEK inhibitors for BRAF-mutant disease) 2. The MASTERKEY-265 trial showed no PFS or OS benefit when adding T-VEC to pembrolizumab 2.

Appropriate Patient Selection

Consider T-VEC for patients with:

• Stage IIIB/C disease with in-transit metastases where surgery is not feasible 5
• Multiple melanoma lesions at different body sites 5
• Rapidly relapsing disease after repeated surgeries 5
• Slowly progressing disease 5
• Contraindications to or refusal of systemic immunotherapy 2

Factors Predicting Poor Response

Multivariate analysis shows reduced likelihood of response in:

• Non-injectable distant metastases at T-VEC initiation (aHR 0.43) 7
• Immunosuppressed patients (aHR 0.18) 7

Important: Prior treatment history (1,2, or ≥3 prior therapies) does NOT significantly reduce response rates 7, making T-VEC viable even in heavily pretreated patients.